Literature DB >> 9783265

Assembly of Clostridium perfringens epsilon-toxin on MDCK cell membrane.

M Nagahama1, S Ochi, J Sakurai.   

Abstract

Clostridium perfringens epsilon-toxin bound to the Madin Darby canine kidney (MDCK) cells and aggregated. The complex of the toxin was formed in a dose- and a time-dependent manner. The formation of the complex increased with a decrease in viable counts of MDCK cells and with increasing K+ release from the cells. The inactivated toxin heated at 100 degrees C did not aggregate under the condition. In addition, the prototoxin dose-dependently bound to the cells, but did not form the complex. Incubation of the toxin with MDCK cell membranes also showed the formation of the complex, but that with membrane preparations prepared from Vero cells or sheep erythrocytes, which are insensitive for the toxin, showed no formation of the complex. Incubation of the toxin with mouse brain homogenates resulted in formation of the complex, but that with brain homogenates heated at 80 degrees C or mouse liver homogenates showed no formation of the complex. These observations show that the complex formation of epsilon-toxin is essential for toxicity of the toxin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9783265

Source DB:  PubMed          Journal:  J Nat Toxins        ISSN: 1058-8108


  14 in total

1.  Binding component of Clostridium perfringens iota-toxin induces endocytosis in Vero cells.

Authors:  Masahiro Nagahama; Koichi Nagayasu; Keiko Kobayashi; Jun Sakurai
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

2.  Accumulation of Clostridium perfringens epsilon-toxin in the mouse kidney and its possible biological significance.

Authors:  Eiji Tamai; Tetsuya Ishida; Shigeru Miyata; Osamu Matsushita; Hirofumi Suda; Shoji Kobayashi; Hiroshi Sonobe; Akinobu Okabe
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

3.  Clostridium perfringens epsilon-toxin increases permeability of single perfused microvessels of rat mesentery.

Authors:  R H Adamson; J C Ly; M Fernandez-Miyakawa; S Ochi; J Sakurai; F Uzal; F E Curry
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

4.  Identification of tyrosine 71 as a critical residue for the cytotoxic activity of Clostridium perfringens epsilon toxin towards MDCK cells.

Authors:  Zhigang Jiang; Jitao Chang; Fang Wang; Li Yu
Journal:  J Microbiol       Date:  2015-01-28       Impact factor: 3.422

5.  Identification of Small Molecule Inhibitors of Clostridium perfringens ε-Toxin Cytotoxicity Using a Cell-Based High-Throughput Screen.

Authors:  Michelle Lewis; Charles David Weaver; Mark S McClain
Journal:  Toxins (Basel)       Date:  2010-07-01       Impact factor: 5.075

6.  Identification of a lambda toxin-negative Clostridium perfringens strain that processes and activates epsilon prototoxin intracellularly.

Authors:  Justine M Harkness; Jihong Li; Bruce A McClane
Journal:  Anaerobe       Date:  2012-09-11       Impact factor: 3.331

7.  Dominant-negative inhibitors of the Clostridium perfringens epsilon-toxin.

Authors:  Teal M Pelish; Mark S McClain
Journal:  J Biol Chem       Date:  2009-08-31       Impact factor: 5.157

Review 8.  The MAL Protein, an Integral Component of Specialized Membranes, in Normal Cells and Cancer.

Authors:  Armando Rubio-Ramos; Leticia Labat-de-Hoz; Isabel Correas; Miguel A Alonso
Journal:  Cells       Date:  2021-04-30       Impact factor: 6.600

9.  Oligomerization of Clostridium perfringens epsilon toxin is dependent upon caveolins 1 and 2.

Authors:  Christine M Fennessey; Jinsong Sheng; Donald H Rubin; Mark S McClain
Journal:  PLoS One       Date:  2012-10-02       Impact factor: 3.240

10.  Clostridium perfringens epsilon toxin H149A mutant as a platform for receptor binding studies.

Authors:  Monika Bokori-Brown; Maria C Kokkinidou; Christos G Savva; Sérgio Fernandes da Costa; Claire E Naylor; Ambrose R Cole; David S Moss; Ajit K Basak; Richard W Titball
Journal:  Protein Sci       Date:  2013-04-08       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.